By staff writers

August 20, 2008 -- Molecular imaging and therapy developer NeuroSurvival Technologies (NST) of Petach-Tikva, Israel, has completed $13.3 million in financing and changed its name.

NST now will be known as Aposense, the same name as the company's molecular imaging agent for programmed cell death.

The Aposense agent, currently under development, is designed to detect signs of apoptosis, a genetically controlled process of cell death that is associated with most medical disorders. Potential clinical applications include oncology, neurology, and cardiology.

IBA, NeuroSurvival Technologies partner, August 14, 2008

NST is cleared for Aposense trials, July 25, 2008

Copyright © 2008


To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking